TRLV Trulieve Cannabis (TRLV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001754195
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
121
13F, latest reported quarter
What the filings say about TRLV
Insiders, 180 days
-$14.7M net sold
1 seller · 0% of sales under a 10b5-1 plan
Trulieve Cannabis insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Trulieve Cannabis Corp. insiders sold a net $14.7M of stock across 7 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 25, 2026.
- The trade is 9.3% of the 1,476,913 shares held after it.
- No other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Rivers Kim A. sold about $1.2M of TRLV on Jun 26, 2026; 121 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 24, 2026.
- The trade is 18.6% of the 1,613,724 shares held after it.
- No other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Rivers Kim A. sold about $2.5M of TRLV on Jun 25, 2026; 121 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 23, 2026.
- The trade is 20.9% of the 1,913,724 shares held after it.
- No other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Rivers Kim A. sold about $3.3M of TRLV on Jun 24, 2026, the largest insider sale at the company on our record; 121 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 22, 2026.
- The trade is 16.4% of the 2,313,724 shares held after it.
- No other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Rivers Kim A. sold about $3.2M of TRLV on Jun 23, 2026, the largest insider sale at the company on our record; 121 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 18, 2026.
- The trade is 7.6% of the 2,693,724 shares held after it.
- No other insider sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Rivers Kim A. sold about $1.9M of TRLV on Jun 22, 2026, the largest insider sale at the company on our record; 121 funds added in the latest 13F quarter.7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$14.7M over 180 days
-$14.7M of it by a 10%+ holder
below 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
121 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
-0.4% year over year
below 57% of Pharma & Biotech
Margin
-10.3% net margin
more than 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.3% of the float short (float per yahoo 2026-10-27) · 4.5 days to cover · settled 2026-10-15
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch TRLV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+41.0%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TRLV: institutional holders (13F)
13F holdings, latest reported quarter
10,641,152 sh
$104.6M
7,500,000 sh
$73.7M
5,065,849 sh
$49.8M
3,250,000 sh
$31.9M
2,665,000 sh
$26.2M
Congress trades in TRLV
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TRLV planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TRLV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Pure Cannabis ETF
$4.5M position · as of 2026-06-30
13.1%
AdvisorShares Pure US Cannabis ETF
$100.1M position · as of 2026-06-30
9.6%
Small Cap Value Fund
$543.7K position · as of 2026-06-30
0.1%
TIFF MULTI-ASSET FUND
$391.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Kim Rivers
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.6M
$11.7M
$879.9K
-73%
-73%
2024
$5.1M
$3.5M
$1.6M
-84%
-78%
2023
$3.4M
$3.8M
$682.3K
-84%
-64%
2022
$3.9M
-$656.2K
$1.4M
-76%
-67%
2021
$8.1M
$7.1M
$2.1M
-18%
-21%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $14.7M sold by insiders over 180 days, 121 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TRLV financials
Revenue growth
-0.4%
XBRL, annual
Net margin
-10.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TRLV
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $938.4M |
| Jun 2026 | $271.0M |
| Mar 2026 | $286.8M |
| Dec 2025 | $293.1M |
| Sep 2025 | $288.2M |
| Jun 2025 | $302.1M |
| Mar 2025 | $297.8M |
| Dec 2024 | $301.1M |
| Sep 2024 | $284.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-41.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TRLV
| FY Dec 2025 | -9.9% |
| FY Dec 2024 | -13.1% |
| FY Dec 2023 | -46.6% |
| FY Dec 2022 | -19.8% |
| FY Dec 2021 | +1.9% |
| Jun 2026 | -149.9% |
| Mar 2026 | +0.8% |
| Dec 2025 | -12.9% |
| Sep 2025 | -10.0% |
| Jun 2025 | -5.3% |
| Mar 2025 | -11.3% |
| Dec 2024 | -18.9% |
| Sep 2024 | -21.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$194.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TRLV
| FY Dec 2025 | $228.6M |
| FY Dec 2024 | $148.9M |
| FY Dec 2023 | $161.6M |
| FY Dec 2022 | -$141.7M |
| FY Dec 2021 | -$263.0M |
| Jun 2026 | $32.1M |
| Mar 2026 | $42.2M |
| Dec 2025 | $55.8M |
| Sep 2025 | $64.1M |
| Jun 2025 | $74.5M |
| Mar 2025 | $34.2M |
| Dec 2024 | -$12.0M |
| Sep 2024 | -$7.8M |
At each fiscal year end
Single quarter
Debt to equity
0.26x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity TRLV
| FY Dec 2025 | 0.12x |
| FY Dec 2024 | 0.29x |
| FY Dec 2023 | 0.26x |
| FY Dec 2022 | 0.28x |
| FY Dec 2021 | 0.22x |
| Jun 2026 | 0.26x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.12x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.30x |
| Mar 2025 | 0.30x |
| Dec 2024 | 0.29x |
| Sep 2024 | 0.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.25x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt TRLV
| FY Dec 2025 | 2.00x |
| FY Dec 2024 | 0.74x |
| FY Dec 2023 | 0.56x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 1.25x |
| Mar 2026 | 1.42x |
| Dec 2025 | 2.00x |
| Sep 2025 | 0.67x |
| Jun 2025 | 0.54x |
| Mar 2025 | 0.50x |
| Dec 2024 | 0.74x |
| Sep 2024 | 1.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-47.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TRLV
| FY Dec 2025 | -9.7% |
| FY Dec 2024 | -11.7% |
| FY Dec 2023 | -31.7% |
| FY Dec 2022 | -12.1% |
| FY Dec 2021 | +1.4% |
| Jun 2026 | -47.6% |
| Mar 2026 | -6.8% |
| Dec 2025 | -9.7% |
| Sep 2025 | -10.9% |
| Jun 2025 | -13.1% |
| Mar 2025 | -12.6% |
| Dec 2024 | -11.7% |
| Sep 2024 | -9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-18.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TRLV
| FY Dec 2025 | -4.2% |
| FY Dec 2024 | -5.5% |
| FY Dec 2023 | -17.2% |
| FY Dec 2022 | -7.2% |
| FY Dec 2021 | +0.9% |
| Jun 2026 | -18.8% |
| Mar 2026 | -2.8% |
| Dec 2025 | -4.2% |
| Sep 2025 | -4.7% |
| Jun 2025 | -5.8% |
| Mar 2025 | -5.8% |
| Dec 2024 | -5.5% |
| Sep 2024 | -4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TRLV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TRLV
| FY Dec 2025 | +5.4% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | -7.6% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +10.3% |
| Jun 2026 | -11.6% |
| Mar 2026 | +5.4% |
| Dec 2025 | +5.4% |
| Sep 2025 | +4.7% |
| Jun 2025 | +3.2% |
| Mar 2025 | +3.1% |
| Dec 2024 | +3.7% |
| Sep 2024 | +4.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TRLV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 118.23x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value TRLV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield TRLV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TRLV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.2B |
| Gross profit | $711.2M | $715.7M | $588.6M | $689.1M |
| Operating income | $143.5M | $97.8M | -$221.6M | $50.2M |
| Net income | -$116.4M | -$155.1M | -$526.8M | -$246.1M |
| EPS (diluted) | -0.58 | -0.79 | -2.28 | -0.95 |
| Operating cash flow | $272.8M | $271.5M | $201.8M | $23.1M |
| Cash | $255.5M | $238.8M | $201.4M | $207.2M |
| Long-term debt | $136.7M | $364.8M | $363.2M | $541.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
TRLV Stock Sonar score 6/7 axes
Find similar shapesCompareTRLV ranks highest on risk and compliance (79th percentile) and institutional and government (74th), and lowest on insider conviction (6th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TRLV filings, in plain words
Are Trulieve Cannabis insiders buying or selling TRLV?
In the 180 days to 2026-10-28, Trulieve Cannabis insiders were net sellers, a net $14.7M across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Trulieve Cannabis insiders were net sellers of TRLV, a net $14.7M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $14.7M, came from a holder of 10% or more rather than an officer or director. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
